# ClinicalTrials.gov record NCT05153590

> PeptideScanner retained ClinicalTrials.gov record NCT05153590 at 2026-07-30T19:32:59.847Z. Its registry update date was 2022-11-17, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct05153590-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-11-17
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05153590-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct05153590-liraglutide-v1.json
- Content SHA-256: `5f8d51f1b7aa1a75b48039c4d6ae7b58d8f2921280887737d3da7c66b6da5e2f`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT05153590 ([`ctg-observation-nct05153590-2022-11-17-0b7ff7017515`](#source-ctg-observation-nct05153590-2022-11-17-0b7ff7017515))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05153590 at 2026-07-30T19:32:59.847Z. Its registry update date was 2022-11-17, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct05153590-2022-11-17-0b7ff7017515`](#source-ctg-observation-nct05153590-2022-11-17-0b7ff7017515))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05153590 at 2026-07-30T19:32:59.847Z. Its registry update date was 2022-11-17, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct05153590-2022-11-17-0b7ff7017515`](#source-ctg-observation-nct05153590-2022-11-17-0b7ff7017515))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05153590-2022-11-17-0b7ff7017515`](#source-ctg-observation-nct05153590-2022-11-17-0b7ff7017515))

## Sources

<a id="source-ctg-observation-nct05153590-2022-11-17-0b7ff7017515"></a>
- **ClinicalTrials.gov record NCT05153590 · retained source version 2022-11-17:0b7ff7017515244ab1b98512492af60a8a4838ad0398b1aa71a49875e29f9657** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05153590) (`ctg-observation-nct05153590-2022-11-17-0b7ff7017515`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05153590." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct05153590-liraglutide-v1.json SHA-256: 5f8d51f1b7aa1a75b48039c4d6ae7b58d8f2921280887737d3da7c66b6da5e2f.